First In Human

FIRST IN HUMAN FEATURED ARTICLES

Every quarter, Synergy Research Group, a full-service CRO headquartered in Moscow, Russia, issues its Orange Paper. The report, which looks at the state of clinical trials in Russia, is comprised of research done by combing through data from the country’s Ministry of Health. The Orange Paper offers a concise snapshot of clinical trials in the region.

The Q2, 2014 Synergy Orange Paper was just released. One of the more significant findings is that the gap between previous years’ trials and the current period is closing. In the first quarter of 2014, there were 18 percent fewer trials than in the same quarter in 2013. In the second quarter, there was a gap of only three percent.

FIRST IN HUMAN WHITE PAPERS & CASE STUDIES

Phase I-IIA Clinical Trials Brochure
At INC Research/inVentiv Health we have the ability to expedite clinical programs and build the foundation for continued development of the product.

More White Papers & Case Studies

FIRST IN HUMAN SERVICES & PRODUCTS

Phase I-IIA Clinical Trials

INC Research/inVentiv Health conducts Phase I-IIa clinical trials quickly and efficiently at its dedicated 22,000 square foot clinical facility comprising more than 200 beds in four independent units. An extensive database and relationships with leading hospitals ensures rapid recruitment of study participants for a wide variety of trials.

First In Human Clinical Trials

Timely and accurate data regarding the safety and efficacy of drug is critical for success at every stage of drug discovery and development.

Cardiac Safety

Cardiac safety concerns can derail your promising product. Failure to evaluate and plan appropriately can leave signals undetected until later, larger studies — a costly scenario. And now regulators expect earlier, more accurate data.

Clinic Profiles

You want to provide a safe environment and a rewarding experience for healthy volunteers during clinical trials. Quintiles delivers that atmosphere, drawing on more than 25 years' experience handling Phase I clinical research and clinical trial monitoring.

Clinical Pharmacology

Clinical Pharmacology — Scientific Steps in Safety, To move from Phase I to Phase IIa and then to guide the dosing-regimen design for Phase III studies.

More Services & Products

NEWS

Immunovative Announces Regulatory Clearance To Conduct A Phase II/III Clinical Trial In Advanced Metastatic Breast Cancer For AlloStim™
Immunovative, Inc. ("IMUN" or the "Company") (OTCQB: IMUN) announces today that Immunovative Therapies, Ltd. ("ITL") has been granted regulatory clearance from Thailand authorities to advance its lead AlloStim™ immunotherapy product candidate to the Phase II/III clinical development stage in advanced metastatic breast cancer.
Kinexum And Pennington Biomedical Announce Collaboration For Accelerating Clinical Research Innovation
Kinexum and Pennington Biomedical Research Center announced plans to establish an integrated approach for emerging companies and early stage therapies to achieve high value regulatory and early phase human clinical trials.
Xcovery Announces Presentation Of Clinical Data At Upcoming ASCO Annual Meeting
Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.
iCardiac Technologies' Growth Accelerates Revenue Growth Exceeds 140% Supported By Expansion Of Operations
iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced recently it has recorded another increase in its growth rate.
Quotient Announces Agreement With Phico Therapeutics And First Application Of RapidFACT For Nasal Delivery Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced an agreement with UK-based biotech, Phico Therapeutics (Phico).
Quotient Announces The First Use Of ivMicrotracer To Support A Regulatory Drug Approval Submission Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), recently announced that absolute bioavailability data from an ivMicrotracer study has been used to support a submission for regulatory drug approval.
Spaulding Clinical Announces Strategic Partnership With Clinigene International, India For Providing Comprehensive Early Clinical Solutions To Pharmaceutical And Biotech Clients Clinigene International Limited, an India-based Central and Bioanalytical Laboratory and Phase I-IV Clinical Research Organization, and Spaulding Clinical Research, LLC, US-based leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a strategic partnership agreement.
Spaulding Clinical Announces New Joint Partnership For Global Studies With Eurofins Optimed Clinical Research Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.
PAREXEL Achieves 100th Asian Ethnobridging Study Milestone PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, announced today that it has achieved a significant milestone by completing its 100th Asian ethnobridging study, which is designed to help biopharmaceutical companies accelerate development for the Asia/Pacific market.
inVentiv Health Completes PharmaNet Acquisition inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.

More News

FIRST IN HUMAN FEATURED ARTICLES

FIRST IN HUMAN WHITE PAPERS & CASE STUDIES

FIRST IN HUMAN SERVICES & PRODUCTS

Newsletter Signup

NEWS